Scotiabank initiated coverage of Travere Therapeutics with an Outperform rating and $23 price target Scotiabank is a buyer of Travere shares after Filspari’s recent conversion to full approval for the treatment of IgA nephropathy in the U.S. and ahead of the expected launch outside the U.S., the analyst tells investors in a research note. While shares have yet to fully recover from the IgAN confirmatory readout last year, as the Filspari launch has continued and full approval with a broader label has been granted, the firm believes Travere’s position in IgAN is strong and the stock is meaningfully undervalued.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics price target raised to $30 from $12 at Evercore ISI
- Travere Therapeutics price target raised to $25 from $17 at Wedbush
- Travere Therapeutics price target raised to $20 from $18 at BofA
- Travere Therapeutics price target raised to $41 from $23 at Guggenheim
- Travere Therapeutics price target raised to $18 from $14 at Barclays